Page 6 - Performance Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article First-line indication offers Canadians with advanced lung cancer new treatment options TORONTO, March 17, 2021 /CNW/ - Takeda Canada Inc. is pleased to announce that Health Canada has issued ALUNBRIG ® (brigatinib tablets) marketing authorization without conditions as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase positive (ALK+) locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). 1 The approval is based on results from the phase 3 ALTA-1L trial which evaluated 275 patients and ...

Share this article Share this article ROCKLAND, Mass., Feb. 3, 2021 /PRNewswire/ -- EMD Serono, the healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO ® (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET) exon 14 skipping alterations. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued...

Prostate cancer expert. at do you think, doctor? was this a misdiagnosis or is there always a chance that a miracle like this can happen for a patient? >> probably it is not not a misdiagnosis. prostate cancer is known to have a prolonged course. many patients live many years with prostate cancer. what determines how long a patient is going to live is patient's age, stage of disease, what kind of treatments he received and other mosh bitty and performance status. that means the patient may have other illnesses that affect survival. it's important to put all of that information together when so...

Latest updates on this topic from reliable sources.